Pathological and metabolic bone diseases. Clinical importance for fracture treatment

被引:0
|
作者
Oheim, R. [1 ,2 ]
机构
[1] Univ Klinikum Schleswig Holstein, Klin Orthopadie & Unfallchirurg, D-23562 Lubeck, Germany
[2] Univ Klinikum Hamburg Eppendorf, Inst Osteol & Biomech, Hamburg, Germany
来源
UNFALLCHIRURG | 2015年 / 118卷 / 12期
关键词
Bone diseases; Osteoporosis; Osteopetrosis; Hypophosphatasia; Paget disease of bone; AUTOSOMAL-DOMINANT OSTEOPETROSIS; PAGETS-DISEASE; ADULT HYPOPHOSPHATASIA; FEMORAL FRACTURES; MANAGEMENT; STABILITY; DIAGNOSIS;
D O I
10.1007/s00113-015-0094-8
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Pathological and metabolic bone diseases are common and relevant occurrences in orthopedics and trauma surgery; however, fractures are often treated as being the illness itself and not seen as the symptom of an underlying bone disease. This is why further diagnostics and systemic treatment options are often insufficiently considered in the routine treatment of fractures. This review focuses on osteoporosis, osteopetrosis, hypophosphatasia and Paget's disease of bone.In patients with osteoporotic vertebral or proximal femur fractures, pharmaceutical treatment to prevent subsequent fractures is an integral part of fracture therapy together with surgical treatment. Osteopetrosis is caused by compromised osteoclastic bone resorption; therefore, even in the face of an elevated bone mass, vitamin D3 supplementation is crucial to avoid clinically relevant hypocalcemia. Unspecific symptoms of the musculoskeletal system, especially together with stress fractures, are typically found in patients suffering from hypophosphatasia. In these patients measurement of alkaline phosphatase shows reduced enzyme activity. Elevated levels of alkaline phosphatase are found in Paget's disease of bone where bisphosphonates are still the treatment of choice.
引用
收藏
页码:1007 / 1016
页数:10
相关论文
共 50 条
  • [21] Drugs for the treatment of metabolic bone diseases
    Drake, Matthew T.
    Cremers, Serge
    Russell, R. Graham
    Bilezikian, John P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (06) : 1049 - 1051
  • [22] Clinical and biochemical footprints of inherited metabolic diseases. IX. Metabolic ear disease
    Bakhos, David
    Blasco, Helene
    Galvin III, John J.
    Ferreira, Carlos R.
    Blau, Nenad
    MOLECULAR GENETICS AND METABOLISM, 2022, 137 (03) : 223 - 229
  • [23] A therapeutic RANKL vaccine for the prevention and treatment of degenerative bone diseases.
    Bratt, T
    Nardi-Dei, V
    Sonderbye-Kjaerulff, L
    Rasmussen, JH
    Lyngso, C
    Tanaka, S
    Hertz, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S275 - S275
  • [24] Clinical and biochemical footprints of inherited metabolic diseases. IV. Metabolic cardiovascular disease
    Ferreira, Carlos R.
    Blau, Nenad
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : 112 - 118
  • [26] DXA is unable to measure differential changes in bone density and microstructure induced by metabolic bone diseases.
    Cory, E.
    Nazarian, A.
    Van der Zwaal, P.
    Hoogwater, F.
    Bohanske, M.
    Snyder, B.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S352 - S352
  • [27] Clinical and biochemical footprints of inherited metabolic diseases. XV. Epilepsies
    Latzer, Itay Tokatly
    Blau, Nenad
    Ferreira, Carlos R.
    Pearl, Phillip L.
    MOLECULAR GENETICS AND METABOLISM, 2023, 140 (03)
  • [28] Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias
    Jerves, Teodoro
    Blau, Nenad
    Ferreira, Carlos R.
    MOLECULAR GENETICS AND METABOLISM, 2022, 136 (02) : 118 - 124
  • [29] Treatment of venereal diseases.
    不详
    BRITISH MEDICAL JOURNAL, 1917, 1917 : 38 - 39
  • [30] Evaluation of a new immunoradiometric assay for human osteocalcin in several metabolic bone diseases.
    Body, JJ
    Wantier, H
    Mathieu, F
    Dumon, JC
    CLINICAL CHEMISTRY, 1996, 42 (06) : 600 - 600